JP6265979B2 - チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 - Google Patents

チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 Download PDF

Info

Publication number
JP6265979B2
JP6265979B2 JP2015517810A JP2015517810A JP6265979B2 JP 6265979 B2 JP6265979 B2 JP 6265979B2 JP 2015517810 A JP2015517810 A JP 2015517810A JP 2015517810 A JP2015517810 A JP 2015517810A JP 6265979 B2 JP6265979 B2 JP 6265979B2
Authority
JP
Japan
Prior art keywords
cell
formula
lymphoma
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015517810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531747A5 (enExample
JP2015531747A (ja
Inventor
ベルトーニ，フランチェスコ
ボネッティ，パオラ
Original Assignee
オンコエシックス ゲーエムベーハー
オンコエシックス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコエシックス ゲーエムベーハー, オンコエシックス ゲーエムベーハー filed Critical オンコエシックス ゲーエムベーハー
Publication of JP2015531747A publication Critical patent/JP2015531747A/ja
Publication of JP2015531747A5 publication Critical patent/JP2015531747A5/ja
Application granted granted Critical
Publication of JP6265979B2 publication Critical patent/JP6265979B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2015517810A 2012-06-25 2013-06-25 チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 Expired - Fee Related JP6265979B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261663885P 2012-06-25 2012-06-25
US61/663,885 2012-06-25
US201261670918P 2012-07-12 2012-07-12
US61/670,918 2012-07-12
PCT/EP2013/063313 WO2014001356A1 (en) 2012-06-25 2013-06-25 Method of treating lymphoma using thienotriazolodiazepine compounds

Publications (3)

Publication Number Publication Date
JP2015531747A JP2015531747A (ja) 2015-11-05
JP2015531747A5 JP2015531747A5 (enExample) 2016-07-28
JP6265979B2 true JP6265979B2 (ja) 2018-01-24

Family

ID=48672651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517810A Expired - Fee Related JP6265979B2 (ja) 2012-06-25 2013-06-25 チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法

Country Status (12)

Country Link
US (1) US20140018353A1 (enExample)
EP (1) EP2863923B1 (enExample)
JP (1) JP6265979B2 (enExample)
KR (1) KR20150045423A (enExample)
CN (1) CN105050605A (enExample)
AU (1) AU2013283378B2 (enExample)
BR (1) BR112014032105A2 (enExample)
CA (1) CA2877434A1 (enExample)
IN (1) IN2014DN11269A (enExample)
MX (1) MX2014015986A (enExample)
RU (1) RU2659171C2 (enExample)
WO (1) WO2014001356A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525563A (ja) * 2013-08-01 2016-08-25 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EA035469B1 (ru) 2013-03-15 2020-06-22 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
JP2016538310A (ja) 2013-11-27 2016-12-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
SMT202000133T1 (it) 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
JP2017514907A (ja) * 2014-05-02 2017-06-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を用いる耐性非ホジキンリンパ腫、髄芽腫及び／又はａｌｋ＋非小細胞肺癌の治療方法
WO2015168621A1 (en) 2014-05-02 2015-11-05 Oncoethix Sa Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
JP2017519727A (ja) 2014-05-08 2017-07-20 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法
CA2951211A1 (en) 2014-06-13 2015-12-17 Oncoethix Gmbh Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds
WO2016026912A1 (en) * 2014-08-19 2016-02-25 Oncoethix Gmbh Methods of treating lymphoma using thienotriazolodiazepine compounds
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
KR101675984B1 (ko) 2015-02-23 2016-11-14 한양대학교 에리카산학협력단 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
CN109715625B (zh) 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
CN108070562A (zh) * 2018-02-03 2018-05-25 金华市中心医院 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法
CA3095912A1 (en) 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
TW202547837A (zh) * 2018-09-11 2025-12-16 瑞士商赫孚孟拉羅股份公司 噻吩并－三唑并－二氮呯醋酸酯
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006802A1 (fr) 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
WO1998011111A1 (en) * 1996-09-13 1998-03-19 Yoshitomi Pharmaceutical Industries, Ltd. Thienotriazolodiazepine compounds and medicinal uses thereof
CN101910182B (zh) * 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
ES2606958T3 (es) * 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
WO2013033420A1 (en) * 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525563A (ja) * 2013-08-01 2016-08-25 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤

Also Published As

Publication number Publication date
KR20150045423A (ko) 2015-04-28
EP2863923B1 (en) 2019-05-08
IN2014DN11269A (enExample) 2015-10-09
CN105050605A (zh) 2015-11-11
BR112014032105A2 (pt) 2017-08-01
WO2014001356A1 (en) 2014-01-03
EP2863923A1 (en) 2015-04-29
AU2013283378A1 (en) 2015-01-29
JP2015531747A (ja) 2015-11-05
CA2877434A1 (en) 2014-01-03
RU2015101106A (ru) 2016-08-10
US20140018353A1 (en) 2014-01-16
MX2014015986A (es) 2016-02-11
RU2659171C2 (ru) 2018-06-28
AU2013283378B2 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
JP2015531747A (ja) チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法
Lee et al. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses
Yan et al. Targeting autophagy to sensitive glioma to temozolomide treatment
Qin et al. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
Costa et al. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor
Lu et al. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
Liu et al. Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway
Liu et al. Apoptosis induced by benzyl isothiocyanate in gefitinib-resistant lung cancer cells is associated with Akt/MAPK pathways and generation of reactive oxygen species
Liu et al. Synergistic killing of lung cancer cells by cisplatin and radiation via autophagy and apoptosis
WO2019058348A1 (en) COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER
Sajithlal et al. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells
Awuah et al. Multilevel pharmacological effects of antipsychotics in potential glioblastoma treatment
Hussain et al. A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis
AU2019261718A1 (en) Cancer treatment
EP3866799A2 (en) Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders
Valinciute et al. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
McCubrey et al. OSU-03012 in the treatment of glioblastoma
RU2742033C2 (ru) Комбинации ингибиторов fgfr4 и секвестрантов желчных кислот
EP4110331B1 (en) Methods of treating dlbcl using btk inhibitors and combinations thereof
Alejandra Pezuk et al. Polo-like kinase 1 pharmacological inhibition as monotherapy or in combination: comparative effects of polo-like kinase 1 inhibition in medulloblastoma cells
Jiang et al. Daily chemical evodiamine from Chinese prickly ash attenuates osteoclast differentiation through RANKL induced NFAT pathways
KR102436875B1 (ko) Pi3 키나아제 억제제 및 bcl-2 억제제를 포함하는 조성물
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor
Zuo et al. Inhibition of Bromodomain-Containing 4 Sensitises Aggressive Non-Hodgkin Lymphomas to Phosphatidylinositol 3-Kinase δ Inhibitors
Cohen et al. A phase I study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in patients with relapsed or refractory lymphoma

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20160222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160222

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171219

R150 Certificate of patent or registration of utility model

Ref document number: 6265979

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees